Thrombolex Inc.

Founded in 2016, Thrombolex, Inc. is engaged in the design, development, manufacture and distribution of innovative endovascular catheters.

11/13/2025

Dr. Vivian Bishay explains how combining mechanical clot disruption with targeted low-dose lytics can maximize effectiveness while minimizing bleeding risk. This streamlined approach delivers faster results, improves workflow for providers, and expands access to advanced therapy for more PE patients.

Thrombolex.com

11/12/2025

During TCT 2025, Dr. Wissam Jaber presented the interim data from Thrombolex's RAPID-PE Study, a prospective, multicenter U.S. study evaluating On-The-Table pharmaco-mechanical lysis for the treatment of PE with the BASHIR™ Endovascular Catheter. The results of the interim analysis demonstrated no deaths or hemodynamic decompensation at 7 days and only one access site bleeding event. The procedure was efficient with a median total time of 43.5 minutes. Only 8% of patients went to the ICU after the procedure and the median length of hospital stay was 2.9 days.

Read the full announcement here: https://thrombolex.com/interim-data-from-the-rapid-pe-study-presented-at-tct-2025/

Thrombolex.com

11/11/2025

Today we honor the courage, sacrifice, and service of all veterans. Thrombolex is grateful for the dedication of those who have served our country and for the freedoms they have protected.

Thrombolex.com

11/10/2025

Thank you to everyone who joined Thrombolex at VEINS 2025. We enjoyed connecting with colleagues, sharing updates on the BASHIR™ Endovascular Catheter, and discussing the latest in venous disease treatment.

We look forward to continuing the conversation and advancing care together.

Thrombolex.com

10/31/2025

Happy Halloween from Thrombolex.

Thrombolex.com

10/26/2025

Today at TCT 2025, join Dr. Wissam Jaber at 12:04 pm in Innovation Session 3: Innovations in Endovascular and Pulmonary Embolism Treatment, as he presents an interim data analysis of the RAPID-PE Study. Results show that on-the-table pharmaco-mechanical lysis (PML) with the BASHIR™ Endovascular Catheter delivers efficient and safe PE therapy that reduces the need for ICU infusion and supports improved patient outcomes.
Thrombolex.com

10/22/2025

In this clip, Dr. Ayman Iskander discusses how the BASHIR™ Endovascular Catheter enhances clinical impact by restoring blood flow quickly and safely, helping patients recover quickly while optimizing hospital resources.

Thrombolex.com

10/20/2025

As TCT 2025 approaches, we invite you to join us for the RAPID-PE Study interim data analysis presented by Dr. Wissam Jaber on Sunday, October 26 at 12:04 pm during Innovation Session 3. This analysis underscores how pharmaco-mechanical lysis (PML) with the BASHIR™ Endovascular Catheter can streamline acute PE therapy by providing efficient and safe treatment that helps avoid the need for post-procedural ICU infusion while supporting improved patient outcomes. Thrombolex is committed to advancing vascular intervention through innovation, collaboration, and solutions that prioritize patient safety.
Thrombolex.com

09/30/2025

Innovation starts with design. The BASHIR™ Endovascular Catheter is engineered to enhance precision and efficacy in the treatment of acute PE, while minimizing complications. Its dual-action expandable infusion basket mechanically fissures the thrombus while delivering targeted thrombolytic therapy. This combined therapy promotes immediate clot resolution.

Thrombolex.com

Address

75 Britain Drive
New Britain, PA
18901

Telephone

+18447926300

Website

http://www.thrombolex.com/

Alerts

Be the first to know and let us send you an email when Thrombolex Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Thrombolex Inc.:

Shortcuts

Want your practice to be the top-listed Clinic in New Britain?